We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

South Korea's Celltrion to Begin Mass Production of Experimental COVID-19 Antibody Drug Ahead of EUA Approval

By HospiMedica International staff writers
Posted on 10 Sep 2020
Print article
Image: South Korea`s Celltrion to Begin Mass Production of Experimental COVID-19 Antibody Drug Ahead of EUA Approval (Photo courtesy of Celltrion Group)
Image: South Korea`s Celltrion to Begin Mass Production of Experimental COVID-19 Antibody Drug Ahead of EUA Approval (Photo courtesy of Celltrion Group)
Celltrion Group (Incheon, South Korea) plans to soon begin commercial production of its experimental COVID-19 antiviral antibody treatment even as the company continues to conduct clinical trials of the antibody drug.

Celltrion had completed identification of antibody candidates for an antiviral treatment in April and announced positive pre-clinical results for its COVID-19 antiviral antibody treatment in June, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2. The treatment became the first COVID-19 antibody drug to be tested on humans in South Korea after receiving regulatory approval in July for clinical trials, stated a report by Reuters.

Celltrion has now reportedly completed Phase 1 trial involving 32 volunteers in South Korea and is enrolling an additional nine participants for another Phase 1 study ahead of later stage trials, for which regulatory reviews are underway. The company is conducting separate overseas human trials of its treatment in the UK, which will be followed by global second and third stage trials in COVID-19 patients with mild and moderate symptoms, according to the Reuters report.

“We have confirmed the safety of the antiviral antibody drug in the process of the local Phase 1 clinical trial,” Kwon Ki-sung, head of Celltrion’s R&D unit, told Reuters.

Related Links:
Celltrion Group

Gold Member
12-Channel ECG
CM1200B
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
X-Ray QA Meter
Piranha CT

Print article

Channels

Critical Care

view channel
Image: AI could help physicians detect abnormal heart rhythms earlier (Photo courtesy of 123RF)

AI to Improved Diagnosis of Atrial Fibrillation

Abnormal heart rhythms frequently arise from—and contribute to—structural abnormalities in the heart. Atrial fibrillation is a specific type of abnormal rhythm that may not be consistently present, often... Read more

Surgical Techniques

view channel
Image: ‘Wraparound’ implants represent a new approach to treating spinal cord injuries (Photo courtesy of 123RF)

Tiny Wraparound Electronic Implants to Revolutionize Treatment of Spinal Cord Injuries

The spinal cord functions as a vital conduit, transmitting nerve impulses to and from the brain, much like a highway. When the spinal cord is damaged, this flow of information is disrupted, leading to... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more